Novel biomarkers in multiple myeloma

      Significant advancements have been made in the molecular mechanisms of myelomagenesis, diagnostic methods, prognostication, and the treatment options in multiple myeloma (MM) over the last decade. Despite these, MM remains a heterogeneous disease with differing outcomes. As myeloma treatment landscape continues to expand, personalized treatment that provides maximum benefit to a specific patient becomes more important. In the last few years, serum monoclonal proteins including the serum-free light chain assays, imaging, and cytogenetics have been used to predict the outcomes of MM patients receiving different types of therapies. With the development of novel technologies, more sensitive detection of residual disease using flow cytometry and next-generation sequencing has been possible. In addition, liquid biopsies using circulating tumor cells, tumor DNA, and novel immune biomarkers are potentially being investigated. These novel potential biomarkers not only accurately detect the mutational landscape of different cancers compared to standard methods but also serve as prognostic and predictive biomarkers for disease relapse and response to therapy. It is likely that we will be able to offer more targeted and risk-adapted therapeutic approach to patients with MM at different stages of their disease guided by these potential biomarkers.


      MM (Multiple Myeloma), ISS (Internationla Staging System), R-ISS (Revised International Staging System), CTCs (Circulating tumor cells), ctDNA (Circulating tumor DNA)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel RL
        • et al.
        Cancer statistics, 2018.
        CA Cancer J Clin. 2018; 68: 7-30
        • Kumar SK
        • Dispenzieri A
        • Lacy MQ
        • et al.
        Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
        Leukemia. 2014; 28: 1122-1128
        • Landgren O
        • Rajkumar SV
        New developments in diagnosis, prognosis, and assessment of response in multiple myeloma.
        Clin Cancer Res. 2016; 22: 5428-5433
        • Durie BG
        • Salmon SE
        A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.
        Cancer. 1975; 36: 842-854
        • Faiman B
        Myeloma genetics and genomics: practice implications and future directions.
        Clin Lymphoma Myeloma Leuk. 2014; 14: 436-440
        • Lohr JG
        • Stojanov P
        • Carter SL
        • et al.
        Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
        Cancer Cell. 2014; 25: 91-101
        • Chapman MA
        • Lawrence MS
        • Keats JJ
        • et al.
        Initial genome sequencing and analysis of multiple myeloma.
        Nature. 2011; 471: 467-472
        • Greipp PR
        • San Miguel J
        • Durie BG
        • et al.
        International staging system for multiple myeloma.
        J Clin Oncol. 2005; 23: 3412-3420
        • Dimopoulos MA
        • Sonneveld P
        • Leung N
        • et al.
        International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment.
        J Clin Oncol. 2016; 34: 1544-1557
        • Palumbo A
        • Avet-Loiseau H
        • Oliva S
        • et al.
        Revised international staging system for multiple myeloma: a report from International Myeloma Working Group.
        J Clin Oncol. 2015; 26: 2863-2869
        • Jimenez-Zepeda VH
        • Reece DE
        • Trudel S
        • Chen C
        • Tiedemann R
        • Kukreti V
        Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.
        Bone Marrow Transplant. 2015; 50: 204-208
        • Ong SY
        • de Mel S
        • Chen YX
        • et al.
        Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group.
        Bone Marrow Transplant. 2016; 51: 933-937
        • Kyle RA
        • Schreiman JS
        • McLeod RA
        • Beabout JW
        Computed tomography in diagnosis and management of multiple myeloma and its variants.
        Arch Intern Med. 1985; 145: 1451-1452
        • Rajkumar SV
        • Dimopoulos MA
        • Palumbo A
        • et al.
        International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
        Lancet Oncol. 2014; 15: e538-e548
        • Zamagni E
        • Patriarca F
        • Nanni C
        • et al.
        Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation.
        Blood. 2011; 118: 5989-5995
        • Usmani SZ
        • Mitchell A
        • Waheed S
        • et al.
        Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
        Blood. 2013; 121: 1819-1823
        • Zamagni E
        • Nanni C
        • Patriarca F
        • et al.
        A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.
        Haematologica. 2007; 92: 50-55
        • Baur-Melnyk A
        • Buhmann S
        • Becker C
        • et al.
        Whole-body MRI versus whole-body MDCT for staging of multiple myeloma.
        Am J Roentgenol. 2008; 190: 1097-1104
        • Moreau P
        • Attal M
        • Caillot D
        • et al.
        Prospective evaluation of magnetic resonance imaging and [(18)F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 trial: results of the IMAJEM study.
        J Clin Oncol. 2017; 35: 2911-2918
        • Bartel TB
        • Haessler J
        • Brown TL
        • et al.
        F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma.
        Blood. 2009; 114: 2068-2076
        • Rasche L
        • Angtuaco E
        • McDonald JE
        • et al.
        Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.
        Blood. 2017; 130: 30-34
        • Martinez-Lopez J
        • Blade J
        • Mateos MV
        • et al.
        Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.
        Blood. 2011; 118: 529-534
        • Kumar S
        • Zhang L
        • Dispenzieri A
        • et al.
        Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.
        Leukemia. 2010; 24: 1498-1505
        • Ozkurt ZN
        • Sucak GT
        • Aki SZ
        • Yagci M
        • Haznedar R
        Early prognostic value of monitoring serum free light chain in patients with multiple myeloma undergoing autologous stem cell transplantation.
        Cancer Invest. 2017; 35: 195-201
        • Koulieris E
        • Panayiotidis P
        • Harding SJ
        • et al.
        Ratio of involved/uninvolved immunoglobulin quantification by Hevylite assay: clinical and prognostic impact in multiple myeloma.
        Exp Hematol Oncol. 2012; 1 (9-3619-1-9): 2162-3619
        • Fonseca R
        • Barlogie B
        • Bataille R
        • et al.
        Genetics and cytogenetics of multiple myeloma: a workshop report.
        Cancer Res. 2004; 64: 1546-1558
        • Munshi NC
        • Anderson KC
        • Bergsagel PL
        • et al.
        Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
        Blood. 2011; 117: 4696-4700
        • Hanamura I
        • Stewart JP
        • Huang Y
        • et al.
        Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from Monoclonal gammopathy of undetermined significance (MGUS) to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation.
        Blood. 2006; 108: 1724-1732
        • Boyd KD
        • Ross FM
        • Walker BA
        • et al.
        Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
        Clin Cancer Res. 2011; 17: 7776-7784
        • San-Miguel J
        • Schlag R
        • Khuageva N
        • et al.
        Superior efficacy with bortezomib plus melphalan-prednisone (VMP) versus melphalan-prednisone (MP) alone in previously untreated multiple myeloma (MM): results of the phase III MMY-3002 VISTA study.
        Haematologica. 2008; 93: 192
        • Avet-Loiseau H
        • Leleu X
        • Roussel M
        • et al.
        Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
        J Clin Oncol. 2010; 28: 4630-4634
        • Walker BA
        • Wardell CP
        • Brioli A
        • et al.
        Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients.
        Blood Cancer J. 2014; 4: e191
        • Avet-Loiseau H
        • Gerson F
        • Magrangeas F
        • et al.
        Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors.
        Blood. 2001; 98: 3082-3086
        • Shaughnessy JDJr
        • Zhan F
        • Burington BE
        • et al.
        A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.
        Blood. 2007; 109: 2276-2284
        • Dickens NJ
        • Walker BA
        • Leone PE
        • et al.
        Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome.
        Clin Cancer Res. 2010; 16: 1856-1864
        • Decaux O
        • Lode L
        • Magrangeas F
        • et al.
        Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome.
        J Clin Oncol. 2008; 26: 4798-4805
        • van de Velde HJ
        • Liu X
        • Chen G
        • Cakana A
        • Deraedt W
        • Bayssas M
        Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.
        Haematologica. 2007; 92: 1399-1406
        • Gay F
        • Larocca A
        • Wijermans P
        • et al.
        Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.
        Blood. 2011; 117: 3025-3031
        • Lahuerta JJ
        • Paiva B
        • Vidriales MB
        • et al.
        Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials.
        J Clin Oncol. 2017; 25 (JCO2016692517): 2900-2910
        • Munshi NC
        • Avet-Loiseau H
        • Rawstron AC
        • et al.
        Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis.
        JAMA Oncol. 2017; 3: 28-35
        • Kumar S
        • Paiva B
        • Anderson KC
        • et al.
        International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
        Lancet Oncol. 2016; 17: e328-e346
      1. NCCN Clinical Practice Guidelines in Oncology. multiple Myeloma Version 4.2018.

        • Paiva B
        • Vidriales MB
        • Cervero J
        • et al.
        Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
        Blood. 2008; 112: 4017-4023
        • Rawstron AC
        • Child JA
        • de Tute RM
        • et al.
        Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study.
        J Clin Oncol. 2013; 31: 2540-2547
        • Paiva B
        • Vídriales MB
        • Montalbán M
        • et al.
        Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
        Am J Pathol. 2012; 181: 1870-1878
        • Paiva B
        • Van Dongen JJ
        • Orfao A
        New criteria for response assessment: role of minimal residual disease in multiple myeloma.
        Blood. 2015; 125: 3059-3068
        • Lipinski E
        • Cremer FW
        • Ho AD
        • Goldschmidt H
        • Moos M
        Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation.
        Bone Marrow Transplant. 2001; 28: 957-962
        • Bakkus MH
        • Bouko Y
        • Samson D
        • et al.
        Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma.
        Br J Haematol. 2004; 126: 665-674
        • Puig N
        • Sarasquete ME
        • Balanzategui A
        • et al.
        Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry.
        Leukemia. 2014; 28: 391-397
        • Martinez-Lopez J
        • Lahuerta JJ
        • Pepin F
        • et al.
        Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.
        Blood. 2014; 123: 3073-3079
        • Avet-Loiseau H
        • et al.
        Evaluation of minimal residual disease (MRD) by next generation sequencing (NGS) is highly predictive of progression free survival in the IFM/DFCI 2009 trial.
        Blood. 2015; 126: 191
        • Oran B
        • Malek K
        • Sanchorawala V
        • et al.
        Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
        Bone Marrow Transplant. 2005; 35: 567-575
        • Walker BA
        • Boyle EM
        • Wardell CP
        • et al.
        Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma.
        J Clin Oncol. 2015; 33: 3911-3920
        • Reinert T
        • Scholer LV
        • Thomsen R
        • et al.
        Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.
        Gut. 2016; 65: 625-634
        • Bettegowda C
        • Sausen M
        • Leary RJ
        • et al.
        Detection of circulating tumor DNA in early- and late-stage human malignancies.
        Sci Transl Med. 2014; 6 (224ra24)
        • Mishima Y
        • Paiva B
        • Shi J
        • et al.
        The mutational landscape of circulating tumor cells in multiple myeloma.
        Cell Rep. 2017; 19: 218-224
        • Vij R
        • Mazumder A
        • Klinger M
        • et al.
        Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
        Clin Lymphoma Myeloma Leuk. 2014; 14 (e1): 131-139
        • Lohr JG
        • Kim S
        • Gould J
        • et al.
        Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.
        Sci Transl Med. 2016; 8 (363ra147)
        • Kis O
        • Kaedbey R
        • Chow S
        • et al.
        Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
        Nat Commun. 2017; 8: 15086
        • Mithraprabhu S
        • Khong T
        • Ramachandran M
        • et al.
        Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.
        Leukemia. 2017; 31: 1695-1705
        • Bianchi G
        • Kyle RA
        • Larson DR
        • et al.
        High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma.
        Leukemia. 2013; 27: 680-685
        • Gonsalves WI
        • Rajkumar SV
        • Dispenzieri A
        • et al.
        Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
        Leukemia. 2017; 31: 130-135
        • Nowakowski GS
        • Witzig TE
        • Dingli D
        • et al.
        Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.
        Blood. 2005; 106: 2276-2279
        • Gonsalves WI
        • Morice WG
        • Rajkumar V
        • et al.
        Quantification of clonal circulating plasma cells in relapsed multiple myeloma.
        Br J Haematol. 2014; 167: 500-505
        • Chakraborty R
        • Muchtar E
        • Kumar S
        • et al.
        Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
        Blood Cancer J. 2016; 6: e512
        • Paiva B
        • Puig N
        • Cedena MT
        • et al.
        Differentiation stage of myeloma plasma cells: biological and clinical significance.
        Leukemia. 2017; 31: 382-392
        • Huhn S
        • Weinhold N
        • Nickel J
        • et al.
        Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.
        Bone Marrow Transplant. 2017; 52: 1194-1198
        • Peceliunas V
        • Janiulioniene A
        • Matuzeviciene R
        • Zvirblis T
        • Griskevicius L
        Circulating plasma cells predict the outcome of relapsed or refractory multiple myeloma.
        Leuk Lymphoma. 2012; 53: 641-647
        • Lonial S
        • Dimopoulos M
        • Palumbo A
        • et al.
        Elotuzumab therapy for relapsed or refractory multiple myeloma.
        N Engl J Med. 2015; 373: 621-631
        • Lokhorst HM
        • Plesner T
        • Laubach JP
        • et al.
        Targeting CD38 with daratumumab monotherapy in multiple myeloma.
        N Engl J Med. 2015; 373: 1207-1219
        • Nijhof IS
        • Casneuf T
        • van Velzen J
        • et al.
        CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.
        Blood. 2016; 128: 959-970
        • Lauss M
        • Donia M
        • Harbst K
        • et al.
        Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
        Nat Commun. 2017; 8 (1738-017-01460-0): 1738-1746
        • Gupta N
        • Khan R
        • Kumar R
        • Kumar L
        • Sharma A
        Versican and its associated molecules: potential diagnostic markers for multiple myeloma.
        Clin Chim Acta. 2015; 442: 119-124
        • Hope C
        • Ollar SJ
        • Heninger E
        • et al.
        TPL2 kinase regulates the inflammatory milieu of the myeloma niche.
        Blood. 2014; 123: 3305-3315
        • Hope C
        • Foulcer S
        • Jagodinsky J
        • et al.
        Immunoregulatory roles of versican proteolysis in the myeloma microenvironment.
        Blood. 2016; 128: 680-685
        • Hope C
        • Emmerich PB
        • Papadas A
        • et al.
        Versican-derived matrikines regulate Batf3-dendritic cell differentiation and promote T cell infiltration in colorectal cancer.
        J Immunol. 2017; 199: 1933-1941
        • Arana P
        • et al.
        High-throughput characterization and new insight into the role of tumor associated macrophages (TAMs) in multiple myeloma.
        Blood. 2016; 128: 482
        • Pagenkopf A
        • et al.
        Versican (VCAN) proteolysis predicts T-cell infiltration in myeloma bone marrow post-autologous stem cell transplant (ASCT).
        Blood. 2017; 130: 1756
        • Schumacher TN
        • Schreiber RD
        Neoantigens in cancer immunotherapy.
        Science. 2015; 348: 69-74
        • Van Allen EM
        • Miao D
        • Schilling B
        • et al.
        Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
        Science. 2015; 350: 207-211
        • Rizvi NA
        • Hellmann MD
        • Snyder A
        • et al.
        Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
        Science. 2015; 348: 124-128
        • Thomas NE
        • Busam KJ
        • From L
        • et al.
        Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
        J Clin Oncol. 2013; 31: 4252-4259
        • Tokito T
        • Azuma K
        • Kawahara A
        • et al.
        Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
        Eur J Cancer. 2016; 55: 7-14
        • Hoyos V
        • Borrello I
        The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
        Blood. 2016; 128: 1679-1687
        • Brown RD
        • Spencer A
        • Ho PJ
        • et al.
        Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma.
        Leuk Lymphoma. 2009; 50: 1860-1864
        • Chung DJ
        • Pronschinske KB
        • Shyer JA
        • et al.
        T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy.
        Cancer Immunol Res. 2016; 4: 61-71
        • Romano A
        • Conticello C
        • Cavalli M
        • et al.
        Immunological dysregulation in multiple myeloma microenvironment.
        Biomed Res Int. 2014; 2014198539
        • Pichiorri F
        • Suh SS
        • Ladetto M
        • et al.
        MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis.
        Proc Natl Acad Sci USA. 2008; 105: 12885-12890
        • Pichiorri F
        • Rocci A
        • Hofmeister CC
        • et al.
        Circulating mir-16 and mir-25 as new prognosticators for multiple myeloma.
        Blood. 2013; 122: 1853